Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : IBIO-201
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
iBio Provides Update on IBIO-201 COVID-19 Vaccine Program
Details : Early functional testing of mouse antisera from IBIO-201 immunized mice demonstrates the presence of antibodies that interfere with the binding of SARS-CoV-2 spike protein sequences to human ACE2 in ex vivo assays.
Product Name : IBIO-201
Product Type : Vaccine
Upfront Cash : Inapplicable
October 08, 2020
Lead Product(s) : IBIO-201
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IBIO-201
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
iBio Announces Second COVID-19 Vaccine Program
Details : The new subunit vaccine (“IBIO-201”) combines antigens derived from the SARS-CoV-2 spike protein fused with the Company’s patented lichenase booster molecule (“LicKM”), which is designed to enhance immune response.
Product Name : IBIO-201
Product Type : Vaccine
Upfront Cash : Inapplicable
April 06, 2020
Lead Product(s) : IBIO-201
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rituximab
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Azargen Biotechnologies
Deal Size : Undisclosed
Deal Type : Agreement
iBio Supporting AzarGen Biotechnologies’ Development of a Rituximab Biosimilar
Details : iBio plans to transfer its proprietary FastPharming Manufacturing System™ to AzarGen in South Africa for production of critical biological medicines for the African continent.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
March 26, 2020
Lead Product(s) : Rituximab
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Azargen Biotechnologies
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
iBio Developing Proprietary COVID-19 Vaccine Candidates
Details : iBio created its SARS-CoV-2 Virus-Like Particle-based constructs in just a few weeks using its FastPharming System™ to produce the nanoparticles in, and purify them from, plants.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 18, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plant Derived Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : CC-Pharming
Deal Size : Undisclosed
Deal Type : Collaboration
iBio and CC-Pharming Initiate Joint Development of Coronavirus Vaccine
Details : Collaboration aims at developing and test new 2019-nCoV vaccine to be manufactured using iBio’s FastPharming System.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
March 02, 2020
Lead Product(s) : Plant Derived Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : CC-Pharming
Deal Size : Undisclosed
Deal Type : Collaboration
iBio Selected to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins
Details : iBio has entered into its first Statement of Work under a Master Services Agreement with Belgium-based ATB Therapeutics (“atbtherapeutics”) to produce its bioengineered antibody-toxin fusion proteins using iBio’s FastPharming® System.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
January 12, 2020